Samantha Zullow

Research often lumps young adults into the 18–65 age group, ignoring crucial developmental and physiological differences. This leads to misguided treatment decisions and missed chances to improve long-term outcomes for conditions like #IBD. Read more: sciencedirect.com/science/articl…

Colorectal cancer is the #1 cause of cancer death in men under 50. This is why #45istheNew50. Our team at #BIDMC_GI is here to help schedule your screening. 📞 617-754-8888 💻 bit.ly/3wGnK5c #ColorectalCancerAwarenessMonth

Stay proactive about your health! If you have IBD, you're at a higher risk of colorectal cancer. Talk to our team today about getting your screening. 📞 617-754-8888 💻 bit.ly/3wGnK5c #ColorectalCancerAwarenessMonth

Common scenario in IBD clinic answered by @sidbarritt4 💎 Isolated HBcAb pts on anti-TNF agents are considered low risk and do not necessarily require HBV prophylaxis @DCharabaty @IBDConference #AIBD2024

One of the best summary slides at #AIBD2024 by Dr. Marla Dubinsky: Specific scenarios for positioning IBD therapy 💉💊 And as Dr. @MLongMD said: “JAKs for joints, ILs for skin” @IBDConference @DrCoreySiegel @MRegueiroMD @CCYANetwork Thank you for a wonderful conference 🔥🔥

#AIBD2024 Algorithm for management for asymptomatic ileitis (incidentally diagnosed terminal ileitis "IDTI" on screening colonoscopy) @IBDConference @tinahamd

Excellent UP treatment algorithm; consider use of topical/rectal tacrolimus before moving on to other advanced therapy. Consider etrasimod given UP subgroup in clinical trials. #AIBD2024 @IBDConference

#AIBD2024 mod-severe UP subgroup seen in etrasimod study; improved outcomes compared to more extensive colitis @IBDConference @mchiorean4

#AIBD2024 clinical trials stopped early due to significant improvement on tacrolimus for refractory UP. Significant clinical and endoscopic improvement seen. @IBDConference @mchiorean4

Live from #AIBD2024: Some non-invasive IBD biomarkers are less reliable in ulcerative proctitis including intestinal ultrasound and fecal calprotectin @IBDConference @mchiorean4

UP risk factors for progression; it is important to explain to patients they have a risk for extension of disease. Up to 20% of pateints require treatment intensification to an advanced therapy #AIBD2024 @IBDConference

@CCYANetwork @IBDConference Congrats! Great work.

We are so proud of 2024 CCYAN Fellow, Maria, for her work on an abstract on medical trauma in young adults with IBD! This abstract was led by young adults with IBD! Learn more by watching the video below! #AIBD2024 ⁦@IBDConference⁩

Looking forward to presenting on April 1st about transition from peds to adult GI care for people with IBD! Hope to see you there @CCYANetwork @CCfdnNewEngland @PediatricIBD #GITwitter #IBD

Our Meta‐analysis is out on @APandT The efficacy of therapeutic drug monitoring of anti‐TNF‐therapy in inflammatory bowel disease onlinelibrary.wiley.com/doi/10.1111/ap… - proactive TDM showing significant benefits! @Jonathansegal85 @Dr_Dee_Kumar @GastroMJB @JonnyBlackwell

Great advice for any #GI fellows interested in #IBD fellowship! Reach out to me if you're interested in @BIDMC_GI for IBD fellowship in the future.

In this article, @IBD_Houston examines safety data on ustekinumab in 🤰. In this cohort of 39 #IBD pregnancies: 🚫 no specific safety concerns with maternal ustekinumab 🚫no congenital anomalies were reported in newborns doi.org/10.1093/crocol…

Results from PAPooSE group on 82 pregnancies among 77 IBD stoma pts. These are high risk pts needing MFM monitoring. @MySMFM @ColorectalDis onlinelibrary.wiley.com/doi/epdf/10.11… -->73% C section (24% emergent) -->24% stoma complication -->7.5% postpartum hemorrhage --> 3/77 had bladder injury

New article @HarvardHealth on #Familyplanning 🫃with #IBD: ▶️Remission before conception is🔑 ▶️Assemble your care team 👨‍⚕️👩‍⚕️🧑‍⚕️ ▶️Make sure💉up-to-date, discuss IBD💊 with your👩‍⚕️👨‍⚕️ #NisaDesai @BIDMC_GI @BIDMC_Medicine rb.gy/oazivw

Congratulations to our 13 #BIDMCGI graduates of the Class of 2022! We are so proud of all you have accomplished - in clinic, in endoscopy, through your research, education, & more - you are clinicians of the highest order and we can’t wait to see what you will accomplish next! 🌟

(1/13)📢 New med option for mod to severe Crohn's disease: Risankizumab-rzaa (Skyrizi) - IL23 antagonist 🏥 Induction: 600 mg IV @ wk 0, 4, 8 (1 hour) 💉Maintenance: 360 mg @ wk 12, then q8 weeks [single-dose prefilled cartridge] ☑️ EIM: psoriatic arthritis, plaque psoriasis